Dr Reddys Laboratories (RDY) Accounts Payables (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Accounts Payables for 18 consecutive years, with $356.0 million the latest figure, recorded in Q1 2026.

• Quarterly Accounts Payables fell 14.63% year-over-year to $356.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356.0 million (down 14.63% YoY) and the FY2026 annual result came in at $356.0 million, down 14.63% from the prior year.
• Accounts Payables eased to $356.0 million in Q1 2026 per RDY's latest filing, from $417.0 million in the prior quarter.
• Over the last five years, Accounts Payables for RDY reached as high as $417.0 million in Q1 2025 and fell as low as $305.0 million in Q2 2022.
• A 5-year average of $349.3 million and a median of $337.0 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables increased 15.22% — and 2026, when it retreated 14.63%.
• Year by year, Accounts Payables stood at $305.0 million in 2022, then grew by 10.49% to $337.0 million in 2023, then gained by 10.09% to $371.0 million in 2024, then gained by 12.4% to $417.0 million in 2025, then slipped by 14.63% to $356.0 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $356.0 million, $417.0 million, and $371.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.